GLP-1 lipid changes, high LDL persistence, and statin decisions

I'm sitting at 90. My doctor does not see 55 as realistic. We will check again in six months.

I agree the coronary calcium score is useful for deciding on statins, especially when calculated risk sits in the intermediate range. It can reflect improvements from weight loss and still flags high risk even after other numbers get better. People who had severe obesity or metabolic syndrome might benefit from checking it even after weight loss. It is not covered by Medicare here but the cost is reasonable and the information is helpful, usually no need to repeat it.

Calcium scoring is a lagging marker for primary prevention. Once calcium appears on the scan you are already developing cardiovascular disease.

True, but the point is that treating everyone with statins is not practical. Decisions rest on estimated 10-year risk of major events, with age the biggest factor followed by family history, smoking, diabetes, blood pressure and lipids. Calcium scoring offers another accurate way to gauge risk and decide on primary prevention. A high score signals established disease and higher risk, while a zero score points to low risk and usually no need for preventive medication unless other calculations say otherwise.

Exactly. I paid for my own CT calcium scan last August and it showed 80 percent blockage in my LCX. A stent in December brought it to zero. The results went to my doctor who started rosuvastatin the same day. LDL dropped from 141 to 54. The blockage came from atherosclerosis. I am staying on the statin because it slows further calcification. Without that scan I might have had a surprise heart attack later.

Good point. I had a calcium CT despite twenty years on a statin keeping cholesterol low and the score came back very high. Now I have a cardiologist. The calcium is stabilizing the artery walls with no narrowing and I pass stress tests while exercising daily. LDL is 40 on a stronger statin and total cholesterol under 100. A high score is not the end, it can prompt earlier action. My trainer at 37 had mild calcification and they are treating aggressively now because of family history.

I agree completely, and it raises a bigger issue. The original poster was likely started on a statin based only on one or two basic LDL estimates without checking those other markers, which is common practice here and not ideal.

I am not a doctor and none of this is medical advice. Start by ignoring the estimated LDL numbers from a standard panel since they use the Friedewald equation and can be off. Even direct LDL-P measures can be skewed during active weight loss. The directly measured values that correlate better with risk are triglycerides and HDL. The triglyceride to HDL ratio is currently one of the stronger estimators of cardiovascular risk.

I cannot speak to those exact links but I would treat anything from the American Heart Association with caution. They have a track record of positions that favor industry and later prove questionable, then sticking with them anyway. Check Cochrane reviews on the same topic for a different angle. Otherwise assume many of their stances mainly steer doctors toward advice that helps industry.

Thanks for the detailed look. I am not a doctor either and would not treat an anonymous comment as advice. I am a strong responder apparently. Blood sugar balanced almost immediately and decades of what felt like constant hypoglycemia disappeared. That let me stop eating constantly just to stay steady. Food noise dropped so eating clean became much easier. I also started strength and cardio training five days a week plus extra hours of activity.

Your case is too complex for me to offer useful thoughts. One broader point though: many large population studies look at total cholesterol and all-cause mortality. All-cause death is harder to manipulate than intermediate markers. When statins lower cholesterol we do not automatically know how that compares to lowering it other ways. Those studies exist but raw data is often not shared with critics, so we rely on the original analyses. What we see from the population data is that very low cholesterol does not always translate to longer life.

I recommend the book Statin Nation by Malcolm Kendrick. He argues statins add only a few days of life on average even in high-risk people, that any benefit may come from nitric oxide effects rather than cholesterol lowering, that side effects are underreported due to industry ties, and that long-lived people with high cholesterol act as counterexamples to the standard theory.

There is probably some truth in those points. The history of statins has enough questionable elements to give pause. Anyone considering a statin should probably pair it with a GLP-1 because of the blood sugar and insulin resistance angle. The GLP-1 will not remove every risk but can help with that part. I still think emerging data will show GLPs are more protective overall than statins, even for people who follow current LDL guidelines.

Most cardiologists and primary doctors will start a low-dose statin such as rosuvastatin five to ten milligrams mainly for its anti-inflammatory effect on arteries rather than just to lower cholesterol. The goal is to limit plaque buildup. That is what my cardiologist explained when my cholesterol was already normal.

My calcium score was 790.

This may not be satisfying but skeptical views matter because rolling out a new test and treatment at population scale can cause real harm if the justification is weak. Obvious harm is the cost of testing many people who do not need it. Less obvious is false positives leading to unnecessary treatment. That is why it is important to call evidence inconclusive when it is. At the individual level a calcium scan can still be worth doing because the cost is low in many places, though they are not as reliable as some hope since plaque can be present without high scores.

Careful readers will notice my position is not that far from the other view. We both accept statins can be useful for secondary prevention. The difference is one side presents them as generally appropriate while I see them as one possible part of a strategy, not something to assume. For primary prevention it always comes down to which studies you select and how you weigh side effects against benefits. I see the evidence as somewhat ambiguous while others treat consensus as certainty, which history shows can be risky. Using the claim that every doctor agrees is circular and does not settle differing study results.

Risking repetition, a drop in triglycerides, especially the ratio to HDL, lines up better with lower heart disease risk than LDL does. If the GLP-1 lowered your triglycerides that counts as a meaningful change.

I need to clarify the sequence: I paid for the calcium scan myself. That scan prompted the cardiologist to order a CT angiogram, which came out blurry, so insurance approved a catheter procedure. While doing that the doctor found something and placed a stent right then. That is the exact order of events.

Someone I know scored far outside the usual tables. Wonder how that turned out. The calcium scan might end up being the best money spent, depending on what follows.

Primary prevention is where the biggest market sits for these drugs. Suppose companies sometimes stretch results or downplay side effects when money is involved. A clear warning sign would be keeping raw trial data locked away so only certain funded groups can analyze it. That is what the group at Oxford appears to be doing with the statin data, citing confidentiality agreements while limiting access.

I would go along if my HDL sat in a normal range, but it is sitting at 30 and even with triglycerides now at 90 the ratio is still unfavorable. The risk profile has not really moved.